MEthylphenidate in ADHD - Addiction(s) Comorbidity: Value of Adding a Cognitive Remediation Program to Improve Short- and Medium-term Therapeutic Response

ConditionADHD-add
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-99
SponsorNantes University Hospital

About this trial

MEthylphenidate in ADHD - Addiction(s) comorbidity: benefit of adding a cognitive remediation program to improve short- and medium-term therapeutic response

Eligibility criteria

Qualifiers

Age over 18;

Diagnosis of ADHD confirmed by DIVA-5 interview following a specialized ADHD-addiction(s) consultation;

Indication for MPH treatment according to European recommendations (J. J. S. Kooij et al., 2019) and absence of contraindications (particularly cardiological);

Presence of at least one comorbid addictive disorder (SUD and/or BA);

Disqualifiers

Presence of disorders of the higher functions or difficulties in reading or writing the French language making it impossible to collect data;

Pregnant or breast-feeding woman;

Person deprived of liberty;

Person under compulsory psychiatric care;

Trial design

Treatments tested in this trial

  • Cognitive remediation program, with the PRESCO® software
  • Control program, with the AUDITICO® software

Treatment groups

248 Participants
are divided into 2 treatment groups

Sponsors and collaborators